{"schema_version":"secwatch.filing_event.v1","accession":"0001439725-25-000003","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.001123+00:00","generated_at":"2026-05-17T17:21:08.443399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M","bullets":["Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).","Gross margin 80% (up 150 bps); net loss $11.5M (+6% YoY); Adjusted EBITDA loss $7.2M.","Reaffirms FY2025 revenue guidance $80-85M; aims for Adjusted EBITDA positive in Q4.","Sales team expanded to 74 reps (+21% YoY); primary care ordering up >100%; digital ordering up 63%.","Development services dollars under contract $12.5M (+54% YoY); ALTITUDE trial enrollment complete."],"urls":{"canonical":"https://secwatch.observer/filing/0001439725-25-000003","json":"https://secwatch.observer/filing/0001439725-25-000003.json","markdown":"https://secwatch.observer/filing/0001439725-25-000003.md","text":"https://secwatch.observer/filing/0001439725-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000143972525000003/0001439725-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000143972525000003/bdsx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:21:08.443399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}